EHP-101 is a patented derivative of cannabidiol (CBD) modified to affect peroxisome-proliferator activator receptor gamma (PPARg) and cannabinoid receptor 2 (CB2) as well as the hypoxia inducible factor (HIF) pathway. These receptors and physiologic pathways are well documented in multiple … Read More
The post Emerald Health Pharmaceuticals’ Cannabinoid -Derived Drug Shows Potential for Remyelination … appeared first on Dagga Magazine.